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The treatment of peritoneal surface malignancies pre-
sents unique and challenging problems to the cancer
clinician. These patients more than many other cancer
patients often suﬀer from signiﬁcant and disabling
symptoms as a direct result of local tumor progression.
As a result, development in this ﬁeld has largely fo-
cused on the disease site rather than histology. Inno-
vative therapies have been largely driven by surgical
oncologists who are often confronted with the chal-
lenge of controlling or palliating the locoregional
progression in the absence of systemic disease. Tradi-
tionally, recurring problems were inevitable, and suc-
cess was transient at best. More recent approaches
have attempted to combine surgical debulking with
locoregional administration of chemotherapy in an
attempt to halt unrelenting locoregional progression of
the disease. Oﬀering innovative therapy to patients
with no standard treatments available is part of what
fulﬁlls our mission as surgical oncologists.
Unfortunately, the ﬁeld of peritoneal surface
malignancies (HIPEC in particular) has a reputation
for being based more on common sense than on
experimental data. The anecdotal data and single-
series reports demonstrate promise, and small
randomized trials have demonstrated remarkable
survival advantages for HIPEC compared with
standard therapy. Reported results for surgically
treated peritoneal surface malignancies combined
with HIPEC are similar to that obtained for other
surgically treated cancers, such as liver resection for
metastatic disease and pancreatic resection for can-
cer. However, the treatment is expensive ﬁnancially
and costly in terms of morbidity and potential eﬀects
on patients’ quality of life. Improved systemic che-
motherapy options create a moving target in terms of
expectations for survival, which makes interpretation
of retrospective series diﬃcult. The ﬁeld is growing in
numbers of practitioners at a considerable pace, but
lagging behind in clinical trials to support the strat-
egy. The easy answer is to run well-controlled phase I,
phase II, and phase III clinical trials. Is this possible?
The study by Harrison et al.1 is an excellent example
of the kind of studies that are needed in the ﬁeld of
peritoneal surface malignancies and regional therapy,
and the authors are to be commended for the enor-
mous effort involved in performing a surgical trial
with HIPEC. As with many well-constructed experi-
ments and clinical trials, the results reported in this
issue leave many questions unanswered and highlight
many of the complexities of performing surgical trials
for peritoneal malignancies.
The manuscript reports a phase I study of an
innovative therapy for patients with peritoneal sur-
face malignancies. The study attempted to deﬁne the
toxicity and feasibility of intraoperative delivery of
liposomal doxorubicin combined with hyperthermia
in a recirculating perfusion of the abdominal cavity (a
procedure known as HIPEC: hyperthermic intra-
peritoneal chemotherapy). In this trial, 21 patients
were enrolled and treated with doses ranging from 15
to 100 mg/m2, with 100 mg/m2 being considered a
safe dose for phase II studies. While no side effects
directly related to the chemotherapy were encoun-
tered, other side effects related to the surgical pro-
cedure were experienced. Pain, discomfort, weight
loss, energy loss, and decreased performance status
accompanies major abdominal surgery and need to
be considered as side effects of the whole treatment.
Unfortunately, this trial failed to reach traditional
phase I end points. An anastomotic leak was
encountered at 100 mg/m2, which might be related to
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the drug impeding healing at that dose, or it might be
caused by a technical mishap, or poor healing related
to malnutrition, carcinomatosis, or hyperthermia.
Nevertheless, the consequence of an anastamotic leak
is quite signiﬁcant, and it would be very difﬁcult to
continue to dose escalate if there was any chance that
the leak was related to the dose of adriamycin. We
have seen similar complications (or toxicities) in
phase I studies that are difﬁcult to deﬁne as drug
related (unpublished). In a phase I study of early
postoperative intraperitoneal 5-FU after HIPEC, we
deﬁned the dose-limiting toxicity of 5-FU as pan-
creatitis, which may well have been a complication
from the debulking or hyperthermia. With the pos-
sibility that it could be related, the dose escalation
was terminated in that study. The maximum tolerated
dose of a drug is therefore very difﬁcult to deﬁne in
the context of HIPEC. Only if the toxicity encoun-
tered is expected based on the systemic proﬁle of the
drug can the dose be considered directly related to the
toxicity.2 This is often not the case with HIPEC, yet
dose escalation must be terminated because of unre-
lated complications making accurate determination
of the maximum tolerated dose difﬁcult.
Even when safe and tolerable doses for intraperi-
toneal chemotherapy can be deﬁned, phase II studies
are even more diﬃcult. These are diﬃcult to fund,
and it is hard to accrue adequate numbers of
appropriate, eligible patients. Once complete, con-
sensus in interpretation of phase II trials in HIPEC is
impossible. Because there is no measurable disease
after surgical cytoreduction and HIPEC, there are no
tumor response measurements. The only objective
endpoints that can be validated are disease-free sur-
vival or overall survival. Survival results must be
compared with the standard of care. Unfortunately,
there are no good studies of modern systemic che-
motherapy regimens in the treatment of isolated
peritoneal carcinomatosis. There is the impression
that these patients do worse than patients with liver
or lung metastases, because abdominal pain and bo-
wel obstruction become life-limiting at relatively
small tumor burdens compared with what would
cause liver or lung failure. However, patients with
isolated peritoneal carcinomatosis are not examined
in large databases such as the SEER database or most
cancer registries. Even controlling for histology,
many factors are presumed to be important in ex-
pected outcome such as the extent of disease before
and after surgery, the disease-free interval prior to
developing carcinomatosis, the tumor doubling time,
and the biological aggressiveness of the cells. Com-
paring diﬀerent HIPEC phase II studies can be dif-
ﬁcult because of variables in terms of drug type and
dose, duration of treatment, level of hyperthermia,
and extent of debulking. These variables combined
with inadequate data on expected outcomes using
standard treatments make phase II HIPEC studies
diﬃcult to perform and interpret.
Finally, phase III studies of HIPEC are even more
diﬃcult to perform and interpret. Single-institutional
studies will not accrue adequate numbers of patients.
Multi-institutional studies are diﬃcult because of
variability in surgeons’ styles, perioperative care, and
diﬀering preconceived notions of how HIPEC should
be delivered. It is diﬃcult to accrue to randomized
trials involving aggressive surgery, because patients
often cannot comprehend that a ‘‘ﬂip of the coin’’
could determine whether or not they undergo pro-
longed surgery with the associated risk of complica-
tions and death or perhaps go untreated for an
imminently terminal condition. In addition, these
trials are diﬃcult to construct because the control
treatment is a moving target that will inevitably place
in doubt conclusions from randomized trials. Finally
the cost per patient of a randomized trial could easily
be between $50,000 and $100,000 if the entire surgery,
drug, and perioperative care is included. Drug com-
panies in general do not fund trials that are designed
to use less of their product in a regional therapy
setting compared with systemic use. The cost is also
too high for device companies, philanthropic funds,
or granting agencies. Even if a randomized trial is
performed and results are positive, it will not deﬁne
which aspect of HIPEC is important. Is it the extent
of debulking, the heat, or the drug that is working?3
Should individual trials be performed examining each
component of the therapy, or should we test the
package as a whole and then tease out the ineffective
parts that have unacceptable side effects later.
Despite these diﬃculties the anecdotal data, retro-
spective reviews, prospective database reports, phase
II studies, and small phase III studies are compelling.
Verwaal et al. reported in the Journal of Clinical
Oncology almost a doubling in median survival for
patients with peritoneal carcinomatosis from colon
cancer (22.3 vs 12.6 months) using HIPEC.4 For
many, this compilation of data is enough to consider
the use of HIPEC as standard therapy.5 For others,
skepticism and intolerance of the high morbidity
associated with HIPEC leads to the pursuit of other
options. So, how do we continue to move the ﬁeld
forward? Realizing the perils discussed above, I be-
lieve that the answer is to keep trying to gather data.
We should continue to perform and publish trials
such as that reported by Harrison et al.1 We need to
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follow outcomes prospectively for those treated as
standard of care. Those interested in this ﬁeld should
standardize treatment approaches and move forward
with multi-institutional phase II and phase III stud-
ies. Surgical and medical oncologists need to combine
strategies. HIPEC should be combined with standard
systemic chemotherapy options to provide incre-
mental improvements rather than compared as an
alternative to systemic chemotherapy. I can only
imagine the multitude of excuses and nihilism that
must have confronted Dr. Bernard Fisher and others
who were performing the early randomized trials that
revolutionized our management of breast cancer.
Many of the excuses at that time would be similar to
that discussed above for HIPEC. Their success
should give present and future surgical oncologist the
courage to forge a new path guided by well-con-
structed clinical trials.
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